Overview of MSC-Derived Exosomes in Ophthalmology: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Kevin Yang Wu and Version 1 by Kevin Yang Wu.

The field of mesenchymal stem cell (MSC) therapy has shown promise in treating ophthalmic diseases. However, MSC-based therapy faces limitations due to suboptimal biocompatibility, penetration, and delivery to the target ocular tissues. To overcome these challenges, researchers have turned their attention to a new aspect of MSCs - their exosomes. These extracellular vesicles possess properties similar to MSCs and can efficiently deliver therapeutic factors to ocular tissues that are typically difficult to target using conventional therapy and MSC transplantation.

Exosomes, small vesicles derived from MSCs, exhibit properties such as anti-inflammatory, anti-apoptotic, and immunomodulatory that are similar to their parent cells. These characteristics make exosomes an attractive alternative to MSCs for ocular therapy. Due to their nano-size, MSC-derived exosomes have the potential to better penetrate biological barriers, such as the blood-retinal barrier, and deliver their cargo effectively to ocular tissues. In addition, their cargo is protected from degradation, leading to increased bioavailability [1-3]. This makes exosomes a promising candidate for ocular drug-delivery applications.

Recent research suggests that MSC-derived exosomes could offer several benefits over traditional MSC-based therapies in the field of regenerative medicine. By using exosomes, practitioners can circumvent potential risks associated with MSC-centered therapies, such as allogeneic immunological rejection, unwanted differentiation, and obstruction of small vessels through intravenous MSC injection. Avoiding these risks is critical for optimizing treatment outcomes. [4]

In this article, we discuss recent developments in the field of MSC-derived exosomes, focusing on publications from 2017 to 2023. We will review the characteristics and functions of MSC exosomes, and their potential for treating anterior and posterior segment ocular diseases. We also explore the potential of exosome-based therapies in clinical contexts, while addressing challenges that must be addressed in preclinical studies, including in vitro and animal-based studies, to facilitate their transition to clinical trials.

  • ophthalmology
  • ocular pharmacology
  • anterior segment diseases
  • posterior segment diseases
  • cell-based drug delivery systems
  • MSCs-based cell therapy
  • MSC-derived exosome
  • exosomes-baseddrug delivery
  • tissue repair and regeneration

Overview of MSC-Derived Exosomes

1. Overview of MSC-Derived Exosomes

Mesenchymal stem cell-derived exosomes (MSC-exosomes) have emerged as potential therapeutic agents in treating various ocular diseases, including traumatic, inflammatory, vascular, and degenerative conditions. Preclinical studies have demonstrated their efficacy in managing autoimmune uveitis, glaucoma, retinal injury, diabetic retinopathy, and optic neuropathy, among others [5–7][1][2][3]. Although further studies are needed, MSC-exosome therapies offer a promising new approach to treat refractory eye diseases.

 

2. Exosomes: Characteristics and Biogenesis

Exosomes: Characteristics and Biogenesis

Extracellular vesicles, which play a crucial role in maintaining cellular homeostasis and are implicated in various pathologies, can be subdivided into exosomes, microvesicles, and apoptotic bodies based on size and biosynthetic pathway. Exosomes, the smallest subset of extracellular vesicles, range from 30 to 150 nm and are composed of a cargo enclosed by a lipid bilayer. The exosomal cargo, consisting of a heterogeneous assemblage of molecules such as proteins, amino acids, metabolites, lipids, and nucleic acids (including, non-exhaustively, DNA, miRNA, mRNA, and lncRNA), is representative of the cell of origin [5, 8][1][4].

Exosomes are membrane-delimited particles that play a vital role in the maintenance of cellular homeostasis and are involved in various pathologies. They are divided into exosomes, microvesicles, and apoptotic bodies based on size and biosynthetic pathway. Exosomes range in size from 30 to 150 nm, and they contain a cargo enclosed by a lipid bilayer, which is representative of the cell of origin. The exosomal cargo consists of a heterogeneous assemblage of proteins, amino acids, metabolites, lipids, and nucleic acids, including DNA, miRNA, mRNA, and lncRNA. Additionally, exosome biogenesis starts with the invagination and budding of the endosomal limiting membrane to form multivesicular bodies (MVBs), which house intraluminal vesicles. The exosomal cargo is sorted via ESCRT-dependent and ESCRT-independent pathways, with the fusion of MVBs with the plasma membrane resulting in the secretion of cup-shaped exosomes into the extracellular environment. The lipid bilayer protects the internal cargo from enzymatic degradation, preserving biological potency and integrity, allowing the exosomes to persist in the ocular structure long after release. Exosomes are optimized for long-distance transport in biological fluids, acting as mediators of intercellular communication upon internalization by target cells and the release of their protected cargo. MSCs have a far greater capacity for exosome production and secretion than cells derived from mesodermal lineages, with adipose tissue, umbilical cord, bone marrow, and corneal stroma being the primary sources of MSC-derived exosomes for the treatment of ocular diseases. Their natural occurrence in bodily fluids and parent-acquired lipid bilayer makes them highly biocompatible. Upon interaction with target cells and the liberation of the enclosed cargo into the intracellular environment, changes in gene expression and cellular function occur. MSC-exosomes are a promising therapeutic agent for a range of refractory ocular diseases, as they can serve as an effective drug delivery system.

 

3. Exosomes in Cellular Communication

Exosomes in Cellular Communication

3.1 The Transfer of Biomolecules and Modulation of Intercellular Communication

The Transfer of Biomolecules and Modulation of Intercellular Communication

MSC-exosomes are important mediators of intercellular communication due to their unique composition of enclosed cargo, which elicits various responses in target cells. One key component is miRNAs, with over 4000 distinct types detected in exosomal cargo. The complement of miRNAs within a given MSC-exosome reflects the identity and state of the donor cell, with each source, including adipose, umbilical cord, and bone marrow-derived MSC-exosomes, housing a unique complement of miRNA types. Upon release in recipient cells, miRNAs post-transcriptionally regulate gene expression by binding to the 30UTR of mRNA. [21-23][5][6][7].

 

3.2. Immunomodulatory Potential in Immune-Mediated Ocular Diseases

Immunomodulatory Potential in Immune-Mediated Ocular Diseases

MSC-exosomes have immense therapeutic potential due to their immunomodulatory, immunosuppresssive, pro-regenerative, pro-angiogenic, and anti-inflammatory properties. Although the eye is an immune-privileged site, immune-mediated ocular disorders can still cause significant damage to ocular tissue. MSC-exosomes have demonstrated efficacy in treating various immune-mediated ocular disorders such as Sjögren’s syndrome dry eye, corneal allograft rejection, and autoimmune uveitis by modulating the overactive immune response that characterizes these pathologies. These diseases share a common underlying mechanism, which involves the promotion of M2 macrophage differentiation and regulatory T cell development, while reducing T-lymphocyte and natural killer cell proliferation [5, 24][1][8].

 

4. Advantages of MSC-Exosomes in Ophthalmology

Advantages of MSC-Exosomes in Ophthalmology

MSC-exosomes offer a safer alternative to MSC transplantation, which carries risks of undesired cell differentiation and inflammation, leading to severe and irreversible complications such as vision loss, vitreous opacification, and retinal detachment. These risks can be reduced with the use of MSC-exosomes, which possess similar therapeutic benefits as MSC transplantation through the secretion of soluble paracrine factors without direct cell replacement. This approach can achieve similar efficacy with a more favorable safety profile [5,25,26][1][9][10].

MSC-exosomes have shown considerable promise as a novel therapeutic agent in the management of ocular diseases due to their efficacy and safety profiles. However, further study is necessary to confirm their potential, particularly in treating diseases refractory to current treatments.

MSC-exosomes can be enhanced through controlled manipulation of chemical, biological, and mechanical factors during parental cell development (MSCs) [14][11], and their cargo can be genetically modified. These optimization techniques are actively being researched to develop them as a novel drug delivery vehicle [5][1].

 

5. MSC-Exosome Isolation and Preservation

MSC-Exosome Isolation and Preservation

The most common method for isolating MSC-exosomes is differential or density-gradient ultracentrifugation [35][12]. However, this procedure is time-consuming, labor-intensive, and may yield impurities [34][13]. Other isolation methods, such as ultrafiltration, size exclusion chromatography, precipitation, and immune affinity capture, can be used instead of ultracentrifugation [34][13]. In addition, size-dependent and immunoaffinity-based microfluidic technologies are emerging as rapid and efficient alternatives [36][14]. While cryopreservation at -80°C is a typical method for long-term storage, concerns about changes in morphology and bioactivity have been raised [37][15]. Cryopreservation with liquid nitrogen and cryoprotective agents may provide superior preservation of exosome morphology and function [19] [16].

 

6. Route of Administration of MSC-Exosomes in Ophthalmology

Route of Administration of MSC-Exosomes in Ophthalmology

MSC-exosomes are typically administered through direct injection into the vitreous humor of the eye in animal models, which allows for high intraocular levels of the therapeutic agent and is well-tolerated by the recipient. However, subconjunctival and periocular injections have also been shown to be effective alternative administration routes. Another mode of delivery is topical application as eye drops, which is minimally invasive but requires higher dosages due to the protective epithelial barrier and rapid tear turnover [17][18]. [38-39]

 

7. Bioengineering MSC-Exosomes for Enhanced Drug Delivery

Bioengineering MSC-Exosomes for Enhanced Drug Delivery

MSC-exosomes have a protective lipid envelope and small size that make them a useful tool for drug delivery. Natural MSC-exosomes contain endogenous biomolecules that can be utilized for therapeutic purposes, but bioengineered exosomes have broader applications [40][19]. Loading of RNA, hydrophilic biological molecules, and proteins into MSC-exosomes can be achieved through transfection, electroporation, and overexpression [41][20]. Alternatively, drugs can be loaded directly into MSCs through transfection, and the secreted MSC-exosomes containing the drug can later be isolated [15][21]. Surface protein modification can improve the specificity of MSC-exosomes to their targets while limiting adverse systemic effects [41][20]. Targeting peptides can be modified on the exosomal surface through covalent modification, non-covalent modification, and genetic engineering to improve targeting specificity [42][22]. Another targeting method involves the use of iron oxide nanoparticles in conjunction with an external magnetic field to localize MSC-exosomes to a specific site of interest [42].

 

[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81][82][83][84][85][86][87][88][89][90][91][92][93][94][95][96][97][98][99][100][101][102][103][104][105][106][107][108][109][110][111][112][113][114][115][116][117][118][119][120][121][122][123][124][125][126][127][128][129][130][131][132][133][134][135][136][137][138][139][140][141][142].

References

  1. Niamprem, P.; Srinivas, S.P.; Tiyaboonchai, W. Penetration of Nile Red-Loaded Nanostructured Lipid Carriers (NLCs) across the Porcine Cornea. Colloids Surf. B Biointerfaces 2019, 176, 371–378. [Google Scholar] [CrossRef] [PubMed]Yu, B.; Li, X.-R.; Zhang, X.-M. Mesenchymal Stem Cell-Derived Extracellular Vesicles as a New Therapeutic Strategy for Ocular Diseases. World J. Stem Cells 2020, 12, 178–187.
  2. Blass, S.; Teubl, B.; Fröhlich, E.; Meindl, C.; Rabensteiner, D.F.; Trummer, G.; Schmut, O.; Zimmer, A.; Roblegg, E. Permeability Studies on the Ocular Absorbance of Nanostructured Materials Across the Cornea. Sci. Pharm. 2010, 78, 678. [Google Scholar] [CrossRef][Green Version]Cui, Y.; Liu, C.; Huang, L.; Chen, J.; Xu, N. Protective Effects of Intravitreal Administration of Mesenchymal Stem Cell-Derived Exosomes in an Experimental Model of Optic Nerve Injury. Exp. Cell Res. 2021, 407, 112792.
  3. Mohammadpour, M.; Hashemi, H.; Jabbarvand, M.; Delrish, E. Penetration of Silicate Nanoparticles into the Corneal Stroma and Intraocular Fluids. Cornea 2014, 33, 738. [Google Scholar] [CrossRef]Zhang, W.; Wang, Y.; Kong, Y. Exosomes Derived from Mesenchymal Stem Cells Modulate MiR-126 to Ameliorate Hyperglycemia-Induced Retinal Inflammation Via Targeting HMGB1. Investig. Opthalmol. Vis. Sci. 2019, 60, 294.
  4. Yu, B.; Shao, H.; Su, C.; Jiang, Y.; Chen, X.; Bai, L.; Zhang, Y.; Li, Q.; Zhang, X.; Li, X. Exosomes Derived from MSCs Ameliorate Retinal Laser Injury Partially by Inhibition of MCP-1. Sci. Rep. 2016, 6, 34562. [Google Scholar] [CrossRef] [PubMed][Green Version]Xu, H.-K.; Chen, L.-J.; Zhou, S.-N.; Li, Y.-F.; Xiang, C. Multifunctional Role of MicroRNAs in Mesenchymal Stem Cell-Derived Exosomes in Treatment of Diseases. World J. Stem Cells 2020, 12, 1276–1294.
  5. Yu, B.; Li, X.-R.; Zhang, X.-M. Mesenchymal Stem Cell-Derived Extracellular Vesicles as a New Therapeutic Strategy for Ocular Diseases. World J. Stem Cells 2020, 12, 178–187. [Google Scholar] [CrossRef] [PubMed]Chen, T.S.; Lai, R.C.; Lee, M.M.; Choo, A.B.H.; Lee, C.N.; Lim, S.K. Mesenchymal Stem Cell Secretes Microparticles Enriched in Pre-MicroRNAs. Nucleic Acids Res. 2010, 38, 215–224.
  6. Cui, Y.; Liu, C.; Huang, L.; Chen, J.; Xu, N. Protective Effects of Intravitreal Administration of Mesenchymal Stem Cell-Derived Exosomes in an Experimental Model of Optic Nerve Injury. Exp. Cell Res. 2021, 407, 112792. [Google Scholar] [CrossRef] [PubMed]Lai, R.C.; Tan, S.S.; Teh, B.J.; Sze, S.K.; Arslan, F.; de Kleijn, D.P.; Choo, A.; Lim, S.K. Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome. Int. J. Proteomics 2012, 2012, 971907.
  7. Zhang, W.; Wang, Y.; Kong, Y. Exosomes Derived from Mesenchymal Stem Cells Modulate MiR-126 to Ameliorate Hyperglycemia-Induced Retinal Inflammation Via Targeting HMGB1. Investig. Opthalmol. Vis. Sci. 2019, 60, 294. [Google Scholar] [CrossRef][Green Version]Glover, K.; Mishra, D.; Singh, T.R.R. Epidemiology of Ocular Manifestations in Autoimmune Disease. Front. Immunol. 2021, 12, 744396.
  8. Xu, H.-K.; Chen, L.-J.; Zhou, S.-N.; Li, Y.-F.; Xiang, C. Multifunctional Role of MicroRNAs in Mesenchymal Stem Cell-Derived Exosomes in Treatment of Diseases. World J. Stem Cells 2020, 12, 1276–1294. [Google Scholar] [CrossRef]Seo, Y.; Kim, H.-S.; Hong, I.-S. Stem Cell-Derived Extracellular Vesicles as Immunomodulatory Therapeutics. Available online: https://www.hindawi.com/journals/sci/2019/5126156/ (accessed on 14 February 2023).
  9. Mathieu, M.; Martin-Jaular, L.; Lavieu, G.; Théry, C. Specificities of Secretion and Uptake of Exosomes and Other Extracellular Vesicles for Cell-to-Cell Communication. Nat. Cell Biol. 2019, 21, 9–17. [Google Scholar] [CrossRef]Kuriyan, A.E.; Albini, T.A.; Townsend, J.H.; Rodriguez, M.; Pandya, H.K.; Leonard, R.E.; Parrott, M.B.; Rosenfeld, P.J.; Flynn, H.W.; Goldberg, J.L. Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMD. N. Engl. J. Med. 2017, 376, 1047–1053.
  10. Van Niel, G.; D’Angelo, G.; Raposo, G. Shedding Light on the Cell Biology of Extracellular Vesicles. Nat. Rev. Mol. Cell Biol. 2018, 19, 213–228. [Google Scholar] [CrossRef]Sun, H.; Pratt, R.E.; Hodgkinson, C.P.; Dzau, V.J. Sequential Paracrine Mechanisms Are Necessary for the Therapeutic Benefits of Stem Cell Therapy. Am. J. Physiol. Cell Physiol. 2020, 319, C1141–C1150.
  11. Xu, M.; Ji, J.; Jin, D.; Wu, Y.; Wu, T.; Lin, R.; Zhu, S.; Jiang, F.; Ji, Y.; Bao, B.; et al. The Biogenesis and Secretion of Exosomes and Multivesicular Bodies (MVBs): Intercellular Shuttles and Implications in Human Diseases. Genes Dis. 2022, S2352304222000976. [Google Scholar] [CrossRef]McKelvey, K.J.; Powell, K.L.; Ashton, A.W.; Morris, J.M.; McCracken, S.A. Exosomes: Mechanisms of Uptake. J. Circ. Biomark. 2015, 4, 7.
  12. Wu, H.; Turner, C.; Gardner, J.; Temple, B.; Brennwald, P. The Exo70 Subunit of the Exocyst Is an Effector for Both Cdc42 and Rho3 Function in Polarized Exocytosis. Mol. Biol. Cell 2010, 21, 430–442. [Google Scholar] [CrossRef] [PubMed][Green Version]Tang, Y.; Zhou, Y.; Li, H.-J. Advances in Mesenchymal Stem Cell Exosomes: A Review. Stem Cell Res. Ther. 2021, 12, 71.
  13. Hung, M.E.; Leonard, J.N. Stabilization of Exosome-Targeting Peptides via Engineered Glycosylation. J. Biol. Chem. 2015, 290, 8166–8172. [Google Scholar] [CrossRef][Green Version]Elliott, R.O.; He, M. Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery. Pharmaceutics 2021, 13, 122.
  14. McKelvey, K.J.; Powell, K.L.; Ashton, A.W.; Morris, J.M.; McCracken, S.A. Exosomes: Mechanisms of Uptake. J. Circ. Biomark. 2015, 4, 7. [Google Scholar] [CrossRef][Green Version]Jia, Y.; Ni, Z.; Sun, H.; Wang, C. Microfluidic Approaches Toward the Isolation and Detection of Exosome Nanovesicles. IEEE Access 2019, 7, 45080–45098.
  15. Bian, B.; Zhao, C.; He, X.; Gong, Y.; Ren, C.; Ge, L.; Zeng, Y.; Li, Q.; Chen, M.; Weng, C.; et al. Exosomes Derived from Neural Progenitor Cells Preserve Photoreceptors during Retinal Degeneration by Inactivating Microglia. J. Extracell. Vesicles 2020, 9, 1748931. [Google Scholar] [CrossRef] [PubMed][Green Version]Zhang, Y.; Bi, J.; Huang, J.; Tang, Y.; Du, S.; Li, P. Exosome: A Review of Its Classification, Isolation Techniques, Storage, Diagnostic and Targeted Therapy Applications. Int. J. Nanomed. 2020, 15, 6917–6934.
  16. Yeo, R.W.Y.; Lai, R.C.; Zhang, B.; Tan, S.S.; Yin, Y.; Teh, B.J.; Lim, S.K. Mesenchymal Stem Cell: An Efficient Mass Producer of Exosomes for Drug Delivery. Adv. Drug Deliv. Rev. 2013, 65, 336–341. [Google Scholar] [CrossRef]Zhang, Z.; Mugisha, A.; Fransisca, S.; Liu, Q.; Xie, P.; Hu, Z. Emerging Role of Exosomes in Retinal Diseases. Front. Cell Dev. Biol. 2021, 9, 643680.
  17. Liu, X.; Hu, L.; Liu, F. Mesenchymal Stem Cell-Derived Extracellular Vesicles for Cell-Free Therapy of Ocular Diseases. Extracell. Vesicles Circ. Nucleic Acids 2022, 3, 102–117. [Google Scholar] [CrossRef]Moisseiev, E.; Anderson, J.D.; Oltjen, S.; Goswami, M.; Zawadzki, R.J.; Nolta, J.A.; Park, S.S. Protective Effect of Intravitreal Administration of Exosomes Derived from Mesenchymal Stem Cells on Retinal Ischemia. Curr. Eye Res. 2017, 42, 1358–1367.
  18. Samaeekia, R.; Rabiee, B.; Putra, I.; Shen, X.; Park, Y.J.; Hematti, P.; Eslani, M.; Djalilian, A.R. Effect of Human Corneal Mesenchymal Stromal Cell-Derived Exosomes on Corneal Epithelial Wound Healing. Investig. Opthalmol. Vis. Sci. 2018, 59, 5194. [Google Scholar] [CrossRef][Green Version]Zhou, T.; He, C.; Lai, P.; Yang, Z.; Liu, Y.; Xu, H.; Lin, X.; Ni, B.; Ju, R.; Yi, W.; et al. MiR-204–Containing Exosomes Ameliorate GVHD-Associated Dry Eye Disease. Sci. Adv. 2022, 8, eabj9617.
  19. Zhang, Z.; Mugisha, A.; Fransisca, S.; Liu, Q.; Xie, P.; Hu, Z. Emerging Role of Exosomes in Retinal Diseases. Front. Cell Dev. Biol. 2021, 9, 643680. [Google Scholar] [CrossRef]Wang, J.; Chen, D.; Ho, E.A. Challenges in the Development and Establishment of Exosome-Based Drug Delivery Systems. J. Control. Release 2021, 329, 894–906.
  20. Boukouris, S.; Mathivanan, S. Exosomes in Bodily Fluids Are a Highly Stable Resource of Disease Biomarkers. PROTEOMICS Clin. Appl. 2015, 9, 358–367. [Google Scholar] [CrossRef][Green Version]Sun, Y.; Liu, G.; Zhang, K.; Cao, Q.; Liu, T.; Li, J. Mesenchymal Stem Cells-Derived Exosomes for Drug Delivery. Stem Cell Res. Ther. 2021, 12, 561.
  21. Chen, T.S.; Lai, R.C.; Lee, M.M.; Choo, A.B.H.; Lee, C.N.; Lim, S.K. Mesenchymal Stem Cell Secretes Microparticles Enriched in Pre-MicroRNAs. Nucleic Acids Res. 2010, 38, 215–224. [Google Scholar] [CrossRef] [PubMed][Green Version]Bian, B.; Zhao, C.; He, X.; Gong, Y.; Ren, C.; Ge, L.; Zeng, Y.; Li, Q.; Chen, M.; Weng, C.; et al. Exosomes Derived from Neural Progenitor Cells Preserve Photoreceptors during Retinal Degeneration by Inactivating Microglia. J. Extracell. Vesicles 2020, 9, 1748931.
  22. Lai, R.C.; Tan, S.S.; Teh, B.J.; Sze, S.K.; Arslan, F.; de Kleijn, D.P.; Choo, A.; Lim, S.K. Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome. Int. J. Proteomics 2012, 2012, 971907. [Google Scholar] [CrossRef] [PubMed][Green Version]Yu, M.; Liu, W.; Li, J.; Lu, J.; Lu, H.; Jia, W.; Liu, F. Exosomes Derived from Atorvastatin-Pretreated MSC Accelerate Diabetic Wound Repair by Enhancing Angiogenesis via AKT/ENOS Pathway. Stem Cell Res. Ther. 2020, 11, 350.
  23. Glover, K.; Mishra, D.; Singh, T.R.R. Epidemiology of Ocular Manifestations in Autoimmune Disease. Front. Immunol. 2021, 12, 744396. [Google Scholar] [CrossRef] [PubMed]
  24. Seo, Y.; Kim, H.-S.; Hong, I.-S. Stem Cell-Derived Extracellular Vesicles as Immunomodulatory Therapeutics. Available online: https://www.hindawi.com/journals/sci/2019/5126156/ (accessed on 14 February 2023).
  25. Kuriyan, A.E.; Albini, T.A.; Townsend, J.H.; Rodriguez, M.; Pandya, H.K.; Leonard, R.E.; Parrott, M.B.; Rosenfeld, P.J.; Flynn, H.W.; Goldberg, J.L. Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMD. N. Engl. J. Med. 2017, 376, 1047–1053. [Google Scholar] [CrossRef][Green Version]
  26. Sun, H.; Pratt, R.E.; Hodgkinson, C.P.; Dzau, V.J. Sequential Paracrine Mechanisms Are Necessary for the Therapeutic Benefits of Stem Cell Therapy. Am. J. Physiol. Cell Physiol. 2020, 319, C1141–C1150. [Google Scholar] [CrossRef]
  27. Zhang, Y.; Liu, Y.; Liu, H.; Tang, W.H. Exosomes: Biogenesis, Biologic Function and Clinical Potential. Cell Biosci. 2019, 9, 19. [Google Scholar] [CrossRef]
  28. Liang, Y.; Duan, L.; Lu, J.; Xia, J. Engineering Exosomes for Targeted Drug Delivery. Theranostics 2021, 11, 3183–3195. [Google Scholar] [CrossRef]
  29. Seyedrazizadeh, S.-Z.; Poosti, S.; Nazari, A.; Alikhani, M.; Shekari, F.; Pakdel, F.; Shahpasand, K.; Satarian, L.; Baharvand, H. Extracellular Vesicles Derived from Human ES-MSCs Protect Retinal Ganglion Cells and Preserve Retinal Function in a Rodent Model of Optic Nerve Injury. Stem Cell Res. Ther. 2020, 11, 203. [Google Scholar] [CrossRef]
  30. Pan, D.; Chang, X.; Xu, M.; Zhang, M.; Zhang, S.; Wang, Y.; Luo, X.; Xu, J.; Yang, X.; Sun, X. UMSC-Derived Exosomes Promote Retinal Ganglion Cells Survival in a Rat Model of Optic Nerve Crush. J. Chem. Neuroanat. 2019, 96, 134–139. [Google Scholar] [CrossRef]
  31. Chen, C.C.; Liu, L.; Ma, F.; Wong, C.W.; Guo, X.E.; Chacko, J.V.; Farhoodi, H.P.; Zhang, S.X.; Zimak, J.; Ségaliny, A.; et al. Elucidation of Exosome Migration across the Blood-Brain Barrier Model In Vitro. Cell. Mol. Bioeng. 2016, 9, 509–529. [Google Scholar] [CrossRef][Green Version]
  32. Li, C.; Qin, S.; Wen, Y.; Zhao, W.; Huang, Y.; Liu, J. Overcoming the Blood-Brain Barrier: Exosomes as Theranostic Nanocarriers for Precision Neuroimaging. J. Control. Release Off. J. Control. Release Soc. 2022, 349, 902–916. [Google Scholar] [CrossRef] [PubMed]
  33. Heidarzadeh, M.; Gürsoy-Özdemir, Y.; Kaya, M.; Eslami Abriz, A.; Zarebkohan, A.; Rahbarghazi, R.; Sokullu, E. Exosomal Delivery of Therapeutic Modulators through the Blood–Brain Barrier; Promise and Pitfalls. Cell Biosci. 2021, 11, 142. [Google Scholar] [CrossRef] [PubMed]
  34. Elliott, R.O.; He, M. Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery. Pharmaceutics 2021, 13, 122. [Google Scholar] [CrossRef] [PubMed]
  35. Tang, Y.; Zhou, Y.; Li, H.-J. Advances in Mesenchymal Stem Cell Exosomes: A Review. Stem Cell Res. Ther. 2021, 12, 71. [Google Scholar] [CrossRef] [PubMed]
  36. Jia, Y.; Ni, Z.; Sun, H.; Wang, C. Microfluidic Approaches Toward the Isolation and Detection of Exosome Nanovesicles. IEEE Access 2019, 7, 45080–45098. [Google Scholar] [CrossRef]
  37. Zhang, Y.; Bi, J.; Huang, J.; Tang, Y.; Du, S.; Li, P. Exosome: A Review of Its Classification, Isolation Techniques, Storage, Diagnostic and Targeted Therapy Applications. Int. J. Nanomed. 2020, 15, 6917–6934. [Google Scholar] [CrossRef]
  38. Moisseiev, E.; Anderson, J.D.; Oltjen, S.; Goswami, M.; Zawadzki, R.J.; Nolta, J.A.; Park, S.S. Protective Effect of Intravitreal Administration of Exosomes Derived from Mesenchymal Stem Cells on Retinal Ischemia. Curr. Eye Res. 2017, 42, 1358–1367. [Google Scholar] [CrossRef][Green Version]
  39. Zhou, T.; He, C.; Lai, P.; Yang, Z.; Liu, Y.; Xu, H.; Lin, X.; Ni, B.; Ju, R.; Yi, W.; et al. MiR-204–Containing Exosomes Ameliorate GVHD-Associated Dry Eye Disease. Sci. Adv. 2022, 8, eabj9617. [Google Scholar] [CrossRef]
  40. Wang, J.; Chen, D.; Ho, E.A. Challenges in the Development and Establishment of Exosome-Based Drug Delivery Systems. J. Control. Release 2021, 329, 894–906. [Google Scholar] [CrossRef]
  41. Sun, Y.; Liu, G.; Zhang, K.; Cao, Q.; Liu, T.; Li, J. Mesenchymal Stem Cells-Derived Exosomes for Drug Delivery. Stem Cell Res. Ther. 2021, 12, 561. [Google Scholar] [CrossRef]
  42. Yu, M.; Liu, W.; Li, J.; Lu, J.; Lu, H.; Jia, W.; Liu, F. Exosomes Derived from Atorvastatin-Pretreated MSC Accelerate Diabetic Wound Repair by Enhancing Angiogenesis via AKT/ENOS Pathway. Stem Cell Res. Ther. 2020, 11, 350. [Google Scholar] [CrossRef]
  43. Wilson, S.E. Corneal Wound Healing. Exp. Eye Res. 2020, 197, 108089. [Google Scholar] [CrossRef]
  44. Du, Y.; SundarRaj, N.; Funderburgh, M.L.; Harvey, S.A.; Birk, D.E.; Funderburgh, J.L. Secretion and Organization of a Cornea-like Tissue In Vitro by Stem Cells from Human Corneal Stroma. Investig. Ophthalmol. Vis. Sci. 2007, 48, 5038–5045. [Google Scholar] [CrossRef] [PubMed]
  45. Sharif, Z.; Sharif, W. Corneal Neovascularization: Updates on Pathophysiology, Investigations & Management. Rom. J. Ophthalmol. 2019, 63, 15–22. [Google Scholar] [PubMed]
  46. Yu, B.; Zhang, X.; Li, X. Exosomes Derived from Mesenchymal Stem Cells. Int. J. Mol. Sci. 2014, 15, 4142–4157. [Google Scholar] [CrossRef] [PubMed][Green Version]
  47. Phinney, D.G.; Pittenger, M.F. Concise Review: MSC-Derived Exosomes for Cell-Free Therapy. Stem Cells 2017, 35, 851–858. [Google Scholar] [CrossRef][Green Version]
  48. Tao, H.; Chen, X.; Cao, H.; Zheng, L.; Li, Q.; Zhang, K.; Han, Z.; Han, Z.-C.; Guo, Z.; Li, Z.; et al. Mesenchymal Stem Cell-Derived Extracellular Vesicles for Corneal Wound Repair. Stem Cells Int. 2019, 2019, 5738510. [Google Scholar] [CrossRef][Green Version]
  49. Yu, Z.; Hao, R.; Du, J.; Wu, X.; Chen, X.; Zhang, Y.; Li, W.; Gu, Z.; Yang, H. A Human Cornea-on-a-Chip for the Study of Epithelial Wound Healing by Extracellular Vesicles. iScience 2022, 25, 104200. [Google Scholar] [CrossRef]
  50. Liu, X.; Li, X.; Wu, G.; Qi, P.; Zhang, Y.; Liu, Z.; Li, X.; Yu, Y.; Ye, X.; Li, Y.; et al. Umbilical Cord Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Deliver MiR-21 to Promote Corneal Epithelial Wound Healing through PTEN/PI3K/Akt Pathway. Stem Cells Int. 2022, 2022, 1252557. [Google Scholar] [CrossRef]
  51. Ma, S.; Yin, J.; Hao, L.; Liu, X.; Shi, Q.; Diao, Y.; Yu, G.; Liu, L.; Chen, J.; Zhong, J. Exosomes from Human Umbilical Cord Mesenchymal Stem Cells Treat Corneal Injury via Autophagy Activation. Front. Bioeng. Biotechnol. 2022, 10, 879192. [Google Scholar] [CrossRef]
  52. Shen, T.; Zheng, Q.-Q.; Shen, J.; Li, Q.-S.; Song, X.-H.; Luo, H.-B.; Hong, C.-Y.; Yao, K. Effects of Adipose-Derived Mesenchymal Stem Cell Exosomes on Corneal Stromal Fibroblast Viability and Extracellular Matrix Synthesis. Chin. Med. J. 2018. Available online: https://mednexus.org/doi/full/10.4103/0366-6999.226889 (accessed on 12 February 2023). [CrossRef] [PubMed]
  53. Du, Y.; Funderburgh, M.L.; Mann, M.M.; SundarRaj, N.; Funderburgh, J.L. Multipotent Stem Cells in Human Corneal Stroma. Stem Cells 2005, 23, 1266–1275. Available online: https://academic.oup.com/stmcls/article/23/9/1266/6399870 (accessed on 12 February 2023). [CrossRef] [PubMed][Green Version]
  54. Du, Y.; Carlson, E.C.; Funderburgh, M.L.; Birk, D.E.; Pearlman, E.; Guo, N.; Kao, W.W.-Y.; Funderburgh, J.L. Stem Cell Therapy Restores Transparency to Defective Murine Corneas. Stem Cells 2009, 27, 1635–1642. Available online: https://academic.oup.com/stmcls/article/27/7/1635/6402401 (accessed on 12 February 2023). [CrossRef][Green Version]
  55. Wang, Y.; Gao, G.; Wu, Y.; Wang, Y.; Wu, X.; Zhou, Q. S100A4 Silencing Facilitates Corneal Wound Healing After Alkali Burns by Promoting Autophagy via Blocking the PI3K/Akt/MTOR Signaling Pathway. Investig. Ophthalmol. Vis. Sci. 2020, 61, 19. [Google Scholar] [CrossRef] [PubMed]
  56. Li, Y.; Jin, R.; Li, L.; Choi, J.S.; Kim, J.; Yoon, H.J.; Park, J.H.; Yoon, K.C. Blue Light Induces Impaired Autophagy through Nucleotide-Binding Oligomerization Domain 2 Activation on the Mouse Ocular Surface. Int. J. Mol. Sci. 2021, 22, 2015. [Google Scholar] [CrossRef] [PubMed]
  57. Tang, Q.; Lu, B.; He, J.; Chen, X.; Fu, Q.; Han, H.; Luo, C.; Yin, H.; Qin, Z.; Lyu, D.; et al. Exosomes-Loaded Thermosensitive Hydrogels for Corneal Epithelium and Stroma Regeneration. Biomaterials 2022, 280, 121320. [Google Scholar] [CrossRef] [PubMed]
  58. Sun, X.; Song, W.; Teng, L.; Huang, Y.; Liu, J.; Peng, Y.; Lu, X.; Yuan, J.; Zhao, X.; Zhao, Q.; et al. MiRNA 24-3p-Rich Exosomes Functionalized DEGMA-Modified Hyaluronic Acid Hydrogels for Corneal Epithelial Healing. Biocative Mater. 2023, 25, 640–656. Available online: https://www.sciencedirect.com/science/article/pii/S2452199X22003097?via%3Dihub (accessed on 12 February 2023). [CrossRef]
  59. Lin, H.; Yiu, S.C. Dry Eye Disease: A Review of Diagnostic Approaches and Treatments. Saudi J. Ophthalmol. Off. J. Saudi Ophthalmol. Soc. 2014, 28, 173–181. [Google Scholar] [CrossRef][Green Version]
  60. Wu, K.Y.; Chen, W.T.; Chu-Bédard, Y.-K.; Patel, G.; Tran, S.D. Management of Sjogren’s Dry Eye Disease—Advances in Ocular Drug Delivery Offering a New Hope. Pharmaceutics 2023, 15, 147. [Google Scholar] [CrossRef]
  61. Lai, P.; Chen, X.; Guo, L.; Wang, Y.; Liu, X.; Liu, Y.; Zhou, T.; Huang, T.; Geng, S.; Luo, C.; et al. A Potent Immunomodulatory Role of Exosomes Derived from Mesenchymal Stromal Cells in Preventing CGVHD. J. Hematol. Oncol. 2018, 11, 135. [Google Scholar] [CrossRef][Green Version]
  62. Zhang, B.; Yeo, R.W.Y.; Lai, R.C.; Sim, E.W.K.; Chin, K.C.; Lim, S.K. Mesenchymal Stromal Cell Exosome–Enhanced Regulatory T-Cell Production through an Antigen-Presenting Cell–Mediated Pathway. Cytotherapy 2018, 20, 687–696. [Google Scholar] [CrossRef] [PubMed]
  63. Guo, R.; Liang, Q.; He, Y.; Wang, C.; Jiang, J.; Chen, T.; Zhang, D.; Hu, K. Mesenchymal Stromal Cells-Derived Extracellular Vesicles Regulate Dendritic Cell Functions in Dry Eye Disease. Cells 2023, 12, 33. [Google Scholar] [CrossRef] [PubMed]
  64. Wang, G.; Li, H.; Long, H.; Gong, X.; Hu, S.; Gong, C. Exosomes Derived from Mouse Adipose-Derived Mesenchymal Stem Cells Alleviate Benzalkonium Chloride-Induced Mouse Dry Eye Model via Inhibiting NLRP3 Inflammasome. Ophthalmic Res. 2022, 65, 40–51. [Google Scholar] [CrossRef] [PubMed]
  65. Yu, C.; Chen, P.; Xu, J.; Liu, Y.; Li, H.; Wang, L.; Di, G. HADSCs Derived Extracellular Vesicles Inhibit NLRP3 inflammasome Activation and Dry Eye. Sci. Rep. 2020, 10, 14521. [Google Scholar] [CrossRef]
  66. Ma, F.; Feng, J.; Liu, X.; Tian, Y.; Wang, W.-J.; Luan, F.-X.; Wang, Y.-J.; Yang, W.-Q.; Bai, J.-Y.; Zhang, Y.-Q.; et al. Ascorbic Acid-Coupled Mesenchymal Stem Cell-Derived Exosomes Ameliorate Dry Eye Disease. Preprints 2020, 2020060316. [Google Scholar] [CrossRef]
  67. Study Record|Beta ClinicalTrials.Gov. Available online: https://beta.clinicaltrials.gov/study/NCT04213248?tab=results (accessed on 13 February 2023).
  68. Zhao, J.; An, Q.; Zhu, X.; Yang, B.; Gao, X.; Niu, Y.; Zhang, L.; Xu, K.; Ma, D. Research Status and Future Prospects of Extracellular Vesicles in Primary Sjögren’s Syndrome. Stem Cell Res. Ther. 2022, 13, 230. [Google Scholar] [CrossRef]
  69. Gong, B.; Zheng, L.; Lu, Z.; Huang, J.; Pu, J.; Pan, S.; Zhang, M.; Liu, J.; Tang, J. Mesenchymal Stem Cells Negatively Regulate CD4+ T Cell Activation in Patients with Primary Sjögren Syndrome through the MiRNA-125b and MiRNA-155 TCR Pathway. Mol. Med. Rep. 2020, 23, 43. [Google Scholar] [CrossRef]
  70. Li, B.; Xing, Y.; Gan, Y.; He, J.; Hua, H. Labial Gland-Derived Mesenchymal Stem Cells and Their Exosomes Ameliorate Murine Sjögren’s Syndrome by Modulating the Balance of Treg and Th17 Cells. Stem Cell Res. Ther. 2021, 12, 478. Available online: https://stemcellres.biomedcentral.com/articles/10.1186/s13287-021-02541-0 (accessed on 13 February 2023). [CrossRef]
  71. Lind, E.F.; Ohashi, P.S. Mir-155, a Central Modulator of T-Cell Responses: Highlights. Eur. J. Immunol. 2014, 44, 11–15. [Google Scholar] [CrossRef]
  72. Rui, K.; Hong, Y.; Zhu, Q.; Shi, X.; Xiao, F.; Fu, H.; Yin, Q.; Xing, Y.; Wu, X.; Kong, X.; et al. Olfactory Ecto-Mesenchymal Stem Cell-Derived Exosomes Ameliorate Murine Sjögren’s Syndrome by Modulating the Function of Myeloid-Derived Suppressor Cells. Cell. Mol. Immunol. 2021, 18, 440–451. [Google Scholar] [CrossRef]
  73. Tomatsu, S.; Pitz, S.; Hampel, U. Ophthalmological Findings in Mucopolysaccharidoses. J. Clin. Med. 2019, 8, 1467. [Google Scholar] [CrossRef] [PubMed][Green Version]
  74. Coulson-Thomas, V.J.; Caterson, B.; Kao, W.W.-Y. Transplantation of Human Umbilical Mesenchymal Stem Cells Cures the Corneal Defects of Mucopolysaccharidosis VII Mice. Stem Cells 2013, 31, 2116–2126. Available online: https://academic.oup.com/stmcls/article/31/10/2116/6408126 (accessed on 13 February 2023). [CrossRef] [PubMed][Green Version]
  75. Flanagan, M.; Pathak, I.; Gan, Q.; Winter, L.; Emnet, R.; Akel, S.; Montaño, A.M. Umbilical Mesenchymal Stem Cell-Derived Extracellular Vesicles as Enzyme Delivery Vehicle to Treat Morquio a Fibroblasts. Stem Cell Res. Ther. 2021, 12, 276. [Google Scholar] [CrossRef] [PubMed]
  76. Doozandeh, A.; Yazdani, S. Neuroprotection in Glaucoma. J. Ophthalmic Vis. Res. 2016, 11, 209–220. [Google Scholar] [CrossRef] [PubMed][Green Version]
  77. Mead, B.; Tomarev, S. Bone Marrow-Derived Mesenchymal Stem Cells-Derived Exosomes Promote Survival of Retinal Ganglion Cells Through MiRNA-Dependent Mechanisms. Stem Cells Transl. Med. 2017, 6, 1273–1285. [Google Scholar] [CrossRef] [PubMed]
  78. Mead, B.; Ahmed, Z.; Tomarev, S. Mesenchymal Stem Cell–Derived Small Extracellular Vesicles Promote Neuroprotection in a Genetic DBA/2J Mouse Model of Glaucoma. Investig. Opthalmol. Vis. Sci. 2018, 59, 5473. [Google Scholar] [CrossRef] [PubMed][Green Version]
  79. Mead, B.; Amaral, J.; Tomarev, S. Mesenchymal Stem Cell–Derived Small Extracellular Vesicles Promote Neuroprotection in Rodent Models of Glaucoma. Investig. Opthalmol. Vis. Sci. 2018, 59, 702. [Google Scholar] [CrossRef]
  80. Mead, B.; Chamling, X.; Zack, D.J.; Ahmed, Z.; Tomarev, S. TNFα-Mediated Priming of Mesenchymal Stem Cells Enhances Their Neuroprotective Effect on Retinal Ganglion Cells. Investig. Opthalmol. Vis. Sci. 2020, 61, 6. [Google Scholar] [CrossRef][Green Version]
  81. Park, M.; Shin, H.A.; Duong, V.-A.; Lee, H.; Lew, H. The Role of Extracellular Vesicles in Optic Nerve Injury: Neuroprotection and Mitochondrial Homeostasis. Cells 2022, 11, 3720. [Google Scholar] [CrossRef]
  82. Berry, M.; Ahmed, Z.; Morgan-Warren, P.; Fulton, D.; Logan, A. Prospects for MTOR-Mediated Functional Repair after Central Nervous System Trauma. Neurobiol. Dis. 2016, 85, 99–110. [Google Scholar] [CrossRef][Green Version]
  83. Park, K.K.; Liu, K.; Hu, Y.; Smith, P.D.; Wang, C.; Cai, B.; Xu, B.; Connolly, L.; Kramvis, I.; Sahin, M.; et al. Promoting Axon Regeneration in the Adult CNS by Modulation of the PTEN/MTOR Pathway. Science 2008, 322, 963–966. [Google Scholar] [CrossRef] [PubMed][Green Version]
  84. Katakowski, M.; Buller, B.; Zheng, X.; Lu, Y.; Rogers, T.; Osobamiro, O.; Shu, W.; Jiang, F.; Chopp, M. Exosomes from Marrow Stromal Cells Expressing MiR-146b Inhibit Glioma Growth. Cancer Lett. 2013, 335, 201–204. [Google Scholar] [CrossRef] [PubMed][Green Version]
  85. Douglas, M.R.; Morrison, K.C.; Jacques, S.J.; Leadbeater, W.E.; Gonzalez, A.M.; Berry, M.; Logan, A.; Ahmed, Z. Off-Target Effects of Epidermal Growth Factor Receptor Antagonists Mediate Retinal Ganglion Cell Disinhibited Axon Growth. Brain 2009, 132, 3102–3121. [Google Scholar] [CrossRef][Green Version]
  86. Koprivica, V.; Cho, K.-S.; Park, J.B.; Yiu, G.; Atwal, J.; Gore, B.; Kim, J.A.; Lin, E.; Tessier-Lavigne, M.; Chen, D.F.; et al. EGFR Activation Mediates Inhibition of Axon Regeneration by Myelin and Chondroitin Sulfate Proteoglycans. Science 2005, 310, 106–110. [Google Scholar] [CrossRef]
  87. Li, H.-J.; Pan, Y.-B.; Sun, Z.-L.; Sun, Y.-Y.; Yang, X.-T.; Feng, D.-F. Inhibition of MiR-21 Ameliorates Excessive Astrocyte Activation and Promotes Axon Regeneration Following Optic Nerve Crush. Neuropharmacology 2018, 137, 33–49. [Google Scholar] [CrossRef]
  88. Meng, F.; Henson, R.; Wehbe–Janek, H.; Ghoshal, K.; Jacob, S.T.; Patel, T. MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer. Gastroenterology 2007, 133, 647–658. [Google Scholar] [CrossRef] [PubMed][Green Version]
  89. Kwon, Y.H.; Fingert, J.H.; Kuehn, M.H.; Alward, W.L.M. Primary Open-Angle Glaucoma. N. Engl. J. Med. 2009, 360, 1113–1124. Available online: https://www.nejm.org/doi/full/10.1056/NEJMra0804630 (accessed on 13 February 2023). [CrossRef] [PubMed][Green Version]
  90. Tabak, S.; Schreiber-Avissar, S.; Beit-Yannai, E. Crosstalk between MicroRNA and Oxidative Stress in Primary Open-Angle Glaucoma. Int. J. Mol. Sci. 2021, 22, 2421. [Google Scholar] [CrossRef]
  91. Li, Y.; Zheng, J.; Wang, X.; Wang, X.; Liu, W.; Gao, J. Mesenchymal Stem Cell-Derived Exosomes Protect Trabecular Meshwork from Oxidative Stress. Sci. Rep. 2021, 11, 14863. [Google Scholar] [CrossRef]
  92. Bradley, J.; Vranka, J.; Colvis, C.; Conger, D.; Alexander, J.; Fisk, A.; Samples, J.; Acott, T. Effect of Matrix Metalloproteinases Activity on Outflow in Perfused Human Organ Culture. Investig. Ophthalmol. Vis. Sci. 1999, 39, 2649–2658. [Google Scholar]
  93. Tamkovich, S.; Grigor’eva, A.; Eremina, A.; Tupikin, A.; Kabilov, M.; Chernykh, V.; Vlassov, V.; Ryabchikova, E. What Information Can Be Obtained from the Tears of a Patient with Primary Open Angle Glaucoma? Clin. Chim. Acta 2019, 495, 529–537. [Google Scholar] [CrossRef] [PubMed]
  94. Pantalon, A.; Obadă, O.; Constantinescu, D.; Feraru, C.; Chiseliţă, D. Inflammatory Model in Patients with Primary Open Angle Glaucoma and Diabetes. Int. J. Ophthalmol. 2019, 12, 795–801. [Google Scholar] [CrossRef] [PubMed]
  95. Li, J.; Zhou, Y.; Long, Q. Effects of Mesenchymal Stem Cells Derived Exosomes on Ultrastructure of Corneal Epithelium and Function of the Tear Film in Dry Eye BALB/c Mice. Investing. Opthalmol. Vis. Sci. 2019, 60, 4187. Available online: https://iovs.arvojournals.org/article.aspx?articleid=2743824 (accessed on 13 February 2023).
  96. Cuenca, N.; Fernández-Sánchez, L.; Campello, L.; Maneu, V.; De la Villa, P.; Lax, P.; Pinilla, I. Cellular Responses Following Retinal Injuries and Therapeutic Approaches for Neurodegenerative Diseases. Prog. Retin. Eye Res. 2014, 43, 17–75. [Google Scholar] [CrossRef] [PubMed]
  97. Deng, C.-L.; Hu, C.-B.; Ling, S.-T.; Zhao, N.; Bao, L.-H.; Zhou, F.; Xiong, Y.-C.; Chen, T.; Sui, B.-D.; Yu, X.-R.; et al. Photoreceptor Protection by Mesenchymal Stem Cell Transplantation Identifies Exosomal MiR-21 as a Therapeutic for Retinal Degeneration. Cell Death Differ. 2021, 28, 1041–1061. [Google Scholar] [CrossRef]
  98. Zhang, J.; Li, P.; Zhao, G.; He, S.; Xu, D.; Jiang, W.; Peng, Q.; Li, Z.; Xie, Z.; Zhang, H.; et al. Mesenchymal Stem Cell-Derived Extracellular Vesicles Protect Retina in a Mouse Model of Retinitis Pigmentosa by Anti-Inflammation through MiR-146a-Nr4a3 Axis. Stem Cell Res. Ther. 2022, 13, 394. [Google Scholar] [CrossRef]
  99. Safwat, A.; Sabry, D.; Ragiae, A.; Amer, E.; Mahmoud, R.H.; Shamardan, R.M. Adipose mesenchymal stem cells–derived exosomes attenuate retina degeneration of streptozotocin-induced diabetes in rabbits. J. Circ. Biomark. 2018, 7, 1849454418807827. [Google Scholar] [CrossRef] [PubMed][Green Version]
  100. Li, W.; Jin, L.; Cui, Y.; Nie, A.; Xie, N.; Liang, G. Bone Marrow Mesenchymal Stem Cells-Induced Exosomal MicroRNA-486-3p Protects against Diabetic Retinopathy through TLR4/NF-ΚB Axis Repression. J. Endocrinol. Investig. 2021, 44, 1193–1207. [Google Scholar] [CrossRef]
  101. Li, W.; Jin, L.; Cui, Y.; Xie, N. Human Umbilical Cord Mesenchymal Stem Cells-Derived Exosomal MicroRNA-17-3p Ameliorates Inflammatory Reaction and Antioxidant Injury of Mice with Diabetic Retinopathy via Targeting STAT1. Int. Immunopharmacol. 2021, 90, 107010. [Google Scholar] [CrossRef]
  102. Gu, C.; Zhang, H.; Zhao, S.; He, D.; Gao, Y. Mesenchymal Stem Cell Exosomal MiR-146a Mediates the Regulation of the TLR4/MyD88/NF-ΚB Signaling Pathway in Inflammation Due to Diabetic Retinopathy. Comput. Math. Methods Med. 2022, 2022, 3864863. [Google Scholar] [CrossRef]
  103. Ebrahim, N.; El-Halim, H.E.A.; Helal, O.K.; El-Azab, N.E.-E.; Badr, O.A.M.; Hassouna, A.; Saihati, H.A.A.; Aborayah, N.H.; Emam, H.T.; El-wakeel, H.S.; et al. Effect of Bone Marrow Mesenchymal Stem Cells-Derived Exosomes on Diabetes-Induced Retinal Injury: Implication of Wnt/b-Catenin Signaling Pathway. Biomed. Pharmacother. 2022, 154, 113554. [Google Scholar] [CrossRef] [PubMed]
  104. Cao, X.; Xue, L.-D.; Di, Y.; Li, T.; Tian, Y.-J.; Song, Y. MSC-Derived Exosomal LncRNA SNHG7 Suppresses Endothelial-Mesenchymal Transition and Tube Formation in Diabetic Retinopathy via MiR-34a-5p/XBP1 Axis. Life Sci. 2021, 272, 119232. [Google Scholar] [CrossRef] [PubMed]
  105. Hajrasouliha, A.R.; Jiang, G.; Lu, Q.; Lu, H.; Kaplan, H.J.; Zhang, H.-G.; Shao, H. Exosomes from Retinal Astrocytes Contain Antiangiogenic Components That Inhibit Laser-Induced Choroidal Neovascularization. J. Biol. Chem. 2013, 288, 28058–28067. [Google Scholar] [CrossRef] [PubMed][Green Version]
  106. He, G.-H.; Zhang, W.; Ma, Y.-X.; Yang, J.; Chen, L.; Song, J.; Chen, S. Mesenchymal Stem Cells-Derived Exosomes Ameliorate Blue Light Stimulation in Retinal Pigment Epithelium Cells and Retinal Laser Injury by VEGF-Dependent Mechanism. Int. J. Ophthalmol. 2018, 11, 559–566. [Google Scholar] [CrossRef]
  107. Mathew, B.; Ravindran, S.; Liu, X.; Torres, L.; Chennakesavalu, M.; Huang, C.-C.; Feng, L.; Zelka, R.; Lopez, J.; Sharma, M.; et al. Mesenchymal Stem Cell-Derived Extracellular Vesicles and Retinal Ischemia-Reperfusion. Biomaterials 2019, 197, 146–160. [Google Scholar] [CrossRef] [PubMed]
  108. Yu, Z.; Wen, Y.; Jiang, N.; Li, Z.; Guan, J.; Zhang, Y.; Deng, C.; Zhao, L.; Zheng, S.G.; Zhu, Y.; et al. TNF-α Stimulation Enhances the Neuroprotective Effects of Gingival MSCs Derived Exosomes in Retinal Ischemia-Reperfusion Injury via the MEG3/MiR-21a-5p Axis. Biomaterials 2022, 284, 121484. [Google Scholar] [CrossRef]
  109. Ma, M.; Li, B.; Zhang, M.; Zhou, L.; Yang, F.; Ma, F.; Shao, H.; Li, Q.; Li, X.; Zhang, X. Therapeutic Effects of Mesenchymal Stem Cell-Derived Exosomes on Retinal Detachment. Exp. Eye Res. 2020, 191, 107899. [Google Scholar] [CrossRef]
  110. Dervenis, N.; Dervenis, P.; Sandinha, T.; Murphy, D.C.; Steel, D.H. Intraocular Tamponade Choice with Vitrectomy and Internal Limiting Membrane Peeling for Idiopathic Macular Hole: A Systematic Review and Meta-Analysis. Ophthalmol. Retina 2022, 6, 457–468. [Google Scholar] [CrossRef]
  111. Muqit, M.M.K.; Hamilton, R.; Ho, J.; Tucker, S.; Buck, H. Intravitreal Ocriplasmin for the Treatment of Vitreomacular Traction and Macular Hole- A Study of Efficacy and Safety Based on NICE Guidance. PLoS ONE 2018, 13, e0197072. [Google Scholar] [CrossRef][Green Version]
  112. Zhang, X.; Liu, J.; Yu, B.; Ma, F.; Ren, X.; Li, X. Effects of Mesenchymal Stem Cells and Their Exosomes on the Healing of Large and Refractory Macular Holes. Graefes Arch. Clin. Exp. Ophthalmol. 2018, 256, 2041–2052. [Google Scholar] [CrossRef]
  113. Valdes, L.M.; Sobrin, L. Uveitis Therapy: The Corticosteroid Options. Drugs 2020, 80, 765–773. [Google Scholar] [CrossRef] [PubMed]
  114. Duplechain, A.; Conrady, C.D.; Patel, B.C.; Baker, S. Uveitis. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2022. [Google Scholar]
  115. Shigemoto-Kuroda, T.; Oh, J.Y.; Kim, D.; Jeong, H.J.; Park, S.Y.; Lee, H.J.; Park, J.W.; Kim, T.W.; An, S.Y.; Prockop, D.J.; et al. MSC-Derived Extracellular Vesicles Attenuate Immune Responses in Two Autoimmune Murine Models: Type 1 Diabetes and Uveoretinitis. Stem Cell Rep. 2017, 8, 1214–1225. [Google Scholar] [CrossRef] [PubMed][Green Version]
  116. Bai, L.; Shao, H.; Wang, H.; Zhang, Z.; Su, C.; Dong, L.; Yu, B.; Chen, X.; Li, X.; Zhang, X. Effects of Mesenchymal Stem Cell-Derived Exosomes on Experimental Autoimmune Uveitis. Sci. Rep. 2017, 7, 4323. [Google Scholar] [CrossRef][Green Version]
  117. Xie, R.; Bai, L.; Yang, J.; Li, Y.; Dong, L.; Ma, F.; Li, X.; Zhang, X. Effects of rat mesenchymal stem cell-derived exosomes on rat experimental autoimmune uveitis. Chin. J. Ocul. Fundus Dis. 2018, 34, 562–567. [Google Scholar]
  118. Li, Y.; Ren, X.; Zhang, Z.; Duan, Y.; Li, H.; Chen, S.; Shao, H.; Li, X.; Zhang, X. Effect of Small Extracellular Vesicles Derived from IL-10-Overexpressing Mesenchymal Stem Cells on Experimental Autoimmune Uveitis. Stem Cell Res. Ther. 2022, 13, 100. [Google Scholar] [CrossRef]
  119. Liu, Y.; Zhou, T.; Yang, Z.; Sun, X.; Huang, Z.; Deng, X.; He, C.; Liu, X. Bone Marrow Mesenchymal Stem Cells-Derived Exosomes Attenuate Neuroinflammation and Promote Survival of Photoreceptor in Retinitis Pigmentosa. Investig. Ophthalmol. Vis. Sci. 2019, 60, 3108. [Google Scholar]
  120. Li, D.; Zhang, J.; Liu, Z.; Gong, Y.; Zheng, Z. Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomal MiR-27b Attenuates Subretinal Fibrosis via Suppressing Epithelial–Mesenchymal Transition by Targeting HOXC6. Stem Cell Res. Ther. 2021, 12, 24. [Google Scholar] [CrossRef] [PubMed]
  121. Oh, J.Y.; Kim, T.W.; Jeong, H.J.; Lee, H.J.; Ryu, J.S.; Wee, W.R.; Heo, J.W.; Kim, M.K. Intraperitoneal Infusion of Mesenchymal Stem/Stromal Cells Prevents Experimental Autoimmune Uveitis in Mice. Mediat. Inflamm. 2014, 2014, 624640. [Google Scholar] [CrossRef] [PubMed][Green Version]
  122. Li, H.; Zhang, Z.; Li, Y.; Su, L.; Duan, Y.; Zhang, H.; An, J.; Ni, T.; Li, X.; Zhang, X. Therapeutic Effect of Rapamycin-Loaded Small Extracellular Vesicles Derived from Mesenchymal Stem Cells on Experimental Autoimmune Uveitis. Front. Immunol. 2022, 13, 864956. [Google Scholar] [CrossRef]
  123. Wei, W.; Ao, Q.; Wang, X.; Cao, Y.; Liu, Y.; Zheng, S.G.; Tian, X. Mesenchymal Stem Cell–Derived Exosomes: A Promising Biological Tool in Nanomedicine. Front. Pharmacol. 2021, 11, 590470. [Google Scholar] [CrossRef]
  124. Hoang, D.M.; Pham, P.T.; Bach, T.Q.; Ngo, A.T.L.; Nguyen, Q.T.; Phan, T.T.K.; Nguyen, G.H.; Le, P.T.T.; Hoang, V.T.; Forsyth, N.R.; et al. Stem Cell-Based Therapy for Human Diseases. Signal Transduct. Target. Ther. 2022, 7, 272. [Google Scholar] [CrossRef] [PubMed]
  125. Kou, M.; Huang, L.; Yang, J.; Chiang, Z.; Chen, S.; Liu, J.; Guo, L.; Zhang, X.; Zhou, X.; Xu, X.; et al. Mesenchymal Stem Cell-Derived Extracellular Vesicles for Immunomodulation and Regeneration: A next Generation Therapeutic Tool? Cell Death Dis. 2022, 13, 580. [Google Scholar] [CrossRef] [PubMed]
  126. Varderidou-Minasian, S.; Lorenowicz, M.J. Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles in Tissue Repair: Challenges and Opportunities. Theranostics 2020, 10, 5979–5997. [Google Scholar] [CrossRef] [PubMed]
  127. Chen, S.; Sun, F.; Qian, H.; Xu, W.; Jiang, J. Preconditioning and Engineering Strategies for Improving the Efficacy of Mesenchymal Stem Cell-Derived Exosomes in Cell-Free Therapy. Stem Cells Int. 2022, 2022, 1779346. [Google Scholar] [CrossRef]
  128. Qazi, T.H.; Mooney, D.J.; Duda, G.N.; Geissler, S. Biomaterials That Promote Cell-Cell Interactions Enhance the Paracrine Function of MSCs. Biomaterials 2017, 140, 103–114. [Google Scholar] [CrossRef]
  129. Su, N.; Gao, P.-L.; Wang, K.; Wang, J.-Y.; Zhong, Y.; Luo, Y. Fibrous Scaffolds Potentiate the Paracrine Function of Mesenchymal Stem Cells: A New Dimension in Cell-Material Interaction. Biomaterials 2017, 141, 74–85. [Google Scholar] [CrossRef]
  130. Samsonraj, R.M.; Rai, B.; Sathiyanathan, P.; Puan, K.J.; Rötzschke, O.; Hui, J.H.; Raghunath, M.; Stanton, L.W.; Nurcombe, V.; Cool, S.M. Establishing Criteria for Human Mesenchymal Stem Cell Potency. Stem Cells 2015, 33, 1878–1891. [Google Scholar] [CrossRef]
  131. Sathiyanathan, P.; Samsonraj, R.M.; Tan, C.L.L.; Ling, L.; Lezhava, A.; Nurcombe, V.; Stanton, L.W.; Cool, S.M. A Genomic Biomarker That Identifies Human Bone Marrow-Derived Mesenchymal Stem Cells with High Scalability. Stem Cells Dayt. Ohio 2020, 38, 1124–1136. [Google Scholar] [CrossRef]
  132. Boulestreau, J.; Maumus, M.; Rozier, P.; Jorgensen, C.; Noël, D. Mesenchymal Stem Cell Derived Extracellular Vesicles in Aging. Front. Cell Dev. Biol. 2020, 8, 107. [Google Scholar] [CrossRef][Green Version]
  133. Li, Y.; Wu, Q.; Wang, Y.; Li, L.; Bu, H.; Bao, J. Senescence of Mesenchymal Stem Cells (Review). Int. J. Mol. Med. 2017, 39, 775–782. [Google Scholar] [CrossRef][Green Version]
  134. Kouroupis, D.; Churchman, S.M.; McGonagle, D.; Jones, E.A. The Assessment of CD146-Based Cell Sorting and Telomere Length Analysis for Establishing the Identity of Mesenchymal Stem Cells in Human Umbilical Cord. F1000Research 2014, 3, 126. [Google Scholar] [CrossRef] [PubMed]
  135. Laschober, G.T.; Brunauer, R.; Jamnig, A.; Fehrer, C.; Greiderer, B.; Lepperdinger, G. Leptin Receptor/CD295 Is Upregulated on Primary Human Mesenchymal Stem Cells of Advancing Biological Age and Distinctly Marks the Subpopulation of Dying Cells. Exp. Gerontol. 2009, 44, 57–62. [Google Scholar] [CrossRef] [PubMed]
  136. Jung, E.M.; Kwon, O.; Kwon, K.-S.; Cho, Y.S.; Rhee, S.K.; Min, J.-K.; Oh, D.-B. Evidences for Correlation between the Reduced VCAM-1 Expression and Hyaluronan Synthesis during Cellular Senescence of Human Mesenchymal Stem Cells. Biochem. Biophys. Res. Commun. 2011, 404, 463–469. [Google Scholar] [CrossRef]
  137. Simmons, P.J.; Torok-Storb, B. Identification of Stromal Cell Precursors in Human Bone Marrow by a Novel Monoclonal Antibody, STRO-1. Blood 1991, 78, 55–62. [Google Scholar] [CrossRef][Green Version]
  138. Yun, S.P.; Han, Y.-S.; Lee, J.H.; Kim, S.M.; Lee, S.H. Melatonin Rescues Mesenchymal Stem Cells from Senescence Induced by the Uremic Toxin p-Cresol via Inhibiting MTOR-Dependent Autophagy. Biomol. Ther. 2018, 26, 389–398. [Google Scholar] [CrossRef] [PubMed]
  139. Chaker, D.; Mouawad, C.; Azar, A.; Quilliot, D.; Achkar, I.; Fajloun, Z.; Makdissy, N. Inhibition of the RhoGTPase Cdc42 by ML141 Enhances Hepatocyte Differentiation from Human Adipose-Derived Mesenchymal Stem Cells via the Wnt5a/PI3K/MiR-122 Pathway: Impact of the Age of the Donor. Stem Cell Res. Ther. 2018, 9, 167. [Google Scholar] [CrossRef] [PubMed][Green Version]
  140. Siegel, G.; Kluba, T.; Hermanutz-Klein, U.; Bieback, K.; Northoff, H.; Schäfer, R. Phenotype, Donor Age and Gender Affect Function of Human Bone Marrow-Derived Mesenchymal Stromal Cells. BMC Med. 2013, 11, 146. [Google Scholar] [CrossRef][Green Version]
  141. Ulum, B.; Teker, H.T.; Sarikaya, A.; Balta, G.; Kuskonmaz, B.; Uckan-Cetinkaya, D.; Aerts-Kaya, F. Bone Marrow Mesenchymal Stem Cell Donors with a High Body Mass Index Display Elevated Endoplasmic Reticulum Stress and Are Functionally Impaired. J. Cell. Physiol. 2018, 233, 8429–8436. [Google Scholar] [CrossRef]
  142. Li, C.; Zhao, H.; Cheng, L.; Wang, B. Allogeneic vs. Autologous Mesenchymal Stem/Stromal Cells in Their Medication Practice. Cell Biosci. 2021, 11, 187. [Google Scholar] [CrossRef]
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Video Production Service
Feedback